Episode Details

Revolution Medicines CEO Dr. Mark Goldsmith joins after the company received FDA approval for its pancreatic cancer pill that's priced at roughly $40,000 per month. Then, Goldman Sachs analyst Jim Schneider shares his reaction to Nvidia's latest earnings report that has the stock jumping. Plus, Synopsys CEO Sassine Ghazi joins on the heels of a beat and raise.
Squawk on the Street Disclaimer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.